search
Back to results

Structural and Functional Correlates of Clinical Response to rTMS Treatment in Schizophrenia Patients With Resistant Auditory Hallucinations (TMSCCS)

Primary Purpose

Schizophrenia

Status
Recruiting
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
Repetitive Transcranial Magnetic Stimulation (rTMS)
Sham Repetitive Transcranial Magnetic Stimulation (rTMS)
Sponsored by
Centre hospitalier de Ville-Evrard, France
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Schizophrenia

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patient with a diagnosis of schizophrenia according to DSM-V (Diagnostic and Statistical Manual of Mental Disorder V, 2013) criteria
  • Clinically stabilized for at least 3 months
  • Patient with resistant auditory hallucinations
  • Male or female, 18 to 65 years old
  • A written agreement from the patient's legal guardian/s, if applicable
  • Right-handed
  • A good knowledge of the French language
  • Signed consent form

Exclusion Criteria:

  • Other diseases than schizophrenia
  • Indulging in an addiction (alcohol, psychoactive substances) over the last 12 months
  • Patient who has received rTMS treatment in the last 12 months
  • Patient who is participating in a concurrent research protocol
  • Patient with a history of seizures
  • rTMS contraindications: patient with epilepsy, brain surgery and/or head trauma in the past, use of cardiac pacemaker, or surgical staples on the scalp
  • MRI contraindications: pregnancy or lactating (n.b. a negative pregnancy test will be required if the patient is a female in reproductive years who does not use contraception); use of cardiac pace maker or surgical staples; patient with a neurological disorder, head trauma or claustrophobia
  • Patient with severe cardiovascular disease
  • Patient with medication which reduces the epileptic threshold (bupropion, methadone and theophylline)
  • Patients placed in psychiatric care either by the state or a third party

Sites / Locations

  • Unité de Recherche Clinique, EPS Ville EvrardRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Sham Comparator

Arm Label

Active Repetitive Transcranial Magnetic Stimulation (rTMS)

Sham Repetitive Transcranial Magnetic Stimulation (rTMS)

Arm Description

low-frequency (1 Hertz) rTMS

sham TMS

Outcomes

Primary Outcome Measures

Changes in the integrity of white matter tracts between responder and non-responder patients
Changes in the variations of the blood-oxygen-dependent level (BOLD) signal between responder and non-responder patients

Secondary Outcome Measures

AHRS (Auditory Hallucinations Rating Scale)
HCS (Hallucinations Change Score)
PANSS (Positive And Negative Syndrome Scale)
PSYRATS (Psychotic Symptom Rating Scale)
BDI (Beck Depression Inventory)
Serum BDNF levels
Measure of the amplitude of Motor-Evoked Potentials (MEPs)

Full Information

First Posted
April 22, 2016
Last Updated
February 8, 2023
Sponsor
Centre hospitalier de Ville-Evrard, France
search

1. Study Identification

Unique Protocol Identification Number
NCT02755623
Brief Title
Structural and Functional Correlates of Clinical Response to rTMS Treatment in Schizophrenia Patients With Resistant Auditory Hallucinations
Acronym
TMSCCS
Official Title
Structural and Functional Correlates of Clinical Response to Repetitive Transcranial Magnetic Stimulation (rTMS) Treatment in Schizophrenia Patients With Resistant Auditory Hallucinations
Study Type
Interventional

2. Study Status

Record Verification Date
February 2023
Overall Recruitment Status
Recruiting
Study Start Date
October 14, 2015 (Actual)
Primary Completion Date
September 8, 2025 (Anticipated)
Study Completion Date
October 8, 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Centre hospitalier de Ville-Evrard, France

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The potential of non-invasive Transcranial Magnetic Stimulation (TMS) as a therapeutic tool for improving schizophrenic symptoms, in particular resistant hallucinations, has been increasingly studied over the past decades. Several studies have demonstrated that low-frequency patterns of repetitive TMS (rTMS) applied over the left Temporoparietal Junction (TPJ), which are known to decrease local activity, significantly reduced auditory verbal hallucinations in schizophrenic patients. In spite of highly promising results, a high level of inter-individual variability in the responses to non-invasive brain stimulation treatments, and the fact that rTMS may prove ineffective in some patients, keep spurring controversy about the efficacy of these approaches (as currently performed), as well as about how to increase its efficacy and consistency. Accordingly, the objectives of this project are to better understand the impact of rTMS on the brains of patients with resistant auditory hallucinations, and to use this information not only to better understand this condition but to develop more efficient and consistent therapies. Thus, in this study, the investigators focus more specifically on resistant auditory hallucinations in schizophrenia, which is a common symptom in schizophrenic patients, and can be treated by rTMS. The investigators hypothesize that there is a baseline difference in anatomical and/or functional connectivity between responder and non-responder patients who are treated with rTMS. Therefore, our project will aim to determine some anatomical and functional connectivity markers of response to rTMS treatment in patients with schizophrenia
Detailed Description
The potential of non-invasive Transcranial Magnetic Stimulation (TMS) as a therapeutic tool for improving schizophrenic symptoms, in particular resistant hallucinations, has been increasingly studied over the past decades. Several studies have demonstrated that low-frequency patterns of repetitive TMS (rTMS) on the left temporoparietal junction (TPJ), which are known to decrease local activity, significantly reduce auditory verbal hallucinations in schizophrenic patients. In spite of highly promising results, a high level of inter-individual variability in the response to non-invasive brain stimulation treatments, and the fact that rTMS may prove ineffective in some patients, keep spurring controversy on the efficacy of these approaches as currently performed, and on how to increase its efficacy and consistency. To date, few studies have aimed to explain this variability when, in fact, a better understanding of this common phenomena in the neurostimulation domain would clearly increase the effectiveness of this treatment, and lead to individualized therapeutic approaches specifically tailored to the conditions of each patient. Moreover, many questions stand, particularly regarding the influence of rTMS treatment on the anatomical and functional connectivity in schizophrenic patients. Accordingly, the objectives of this project are to better understand the impact of rTMS on the brains of patients with resistant auditory hallucinations, and to use this information not only to better understand this condition but to develop more efficient and consistent therapies. The investigators hypothesize that there is a baseline difference in anatomical and/or functional connectivity between responder and non-responder patients who are treated with rTMS. Therefore, this project aims to determine some anatomical and functional connectivity markers of response to rTMS treatment in patients with schizophrenia. For this, the investigators compare the patterns of diffusion tensor imaging (DTI) white matter tractography and resting-state functional magnetic resonance imaging (fMRI) data between responder and non-responder patients to rTMS treatment. Moreover, the investigators believe that rTMS can increase the functional connectivity between frontal and temporo-parietal cortices in schizophrenic patients associated with improvements in auditory hallucinations. Therefore, the second objectives of this work are to evaluate the impact of rTMS in functional connectivity in patients with schizophrenia by comparing the DTI and resting-state fMRI data before and after rTMS treatment in both responder and non-responder patients.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Schizophrenia

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
45 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Active Repetitive Transcranial Magnetic Stimulation (rTMS)
Arm Type
Active Comparator
Arm Description
low-frequency (1 Hertz) rTMS
Arm Title
Sham Repetitive Transcranial Magnetic Stimulation (rTMS)
Arm Type
Sham Comparator
Arm Description
sham TMS
Intervention Type
Device
Intervention Name(s)
Repetitive Transcranial Magnetic Stimulation (rTMS)
Intervention Description
Participants are sequentially randomly assigned to either 20 active rTMS sessions or 20 sham rTMS sessions that were applied over the left temporoparietal junction. Treatments are administered daily, over a period of two weeks.
Intervention Type
Device
Intervention Name(s)
Sham Repetitive Transcranial Magnetic Stimulation (rTMS)
Primary Outcome Measure Information:
Title
Changes in the integrity of white matter tracts between responder and non-responder patients
Time Frame
Baseline
Title
Changes in the variations of the blood-oxygen-dependent level (BOLD) signal between responder and non-responder patients
Time Frame
Baseline
Secondary Outcome Measure Information:
Title
AHRS (Auditory Hallucinations Rating Scale)
Time Frame
Baseline, 3 weeks, 7 weeks and 15 weeks
Title
HCS (Hallucinations Change Score)
Time Frame
Baseline, 3 weeks, 7 weeks and 15 weeks
Title
PANSS (Positive And Negative Syndrome Scale)
Time Frame
Baseline, 3 weeks, 7 weeks and 15 weeks
Title
PSYRATS (Psychotic Symptom Rating Scale)
Time Frame
Baseline, 3 weeks, 7 weeks and 15 weeks
Title
BDI (Beck Depression Inventory)
Time Frame
Baseline, 3 weeks, 7 weeks and 15 weeks
Title
Serum BDNF levels
Time Frame
Baseline, 3 weeks, 7 weeks and 15 weeks
Title
Measure of the amplitude of Motor-Evoked Potentials (MEPs)
Time Frame
Baseline, 3 weeks, 7 weeks and 15 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patient with a diagnosis of schizophrenia according to DSM-V (Diagnostic and Statistical Manual of Mental Disorder V, 2013) criteria Clinically stabilized for at least 3 months Patient with resistant auditory hallucinations Male or female, 18 to 65 years old A written agreement from the patient's legal guardian/s, if applicable Right-handed A good knowledge of the French language Signed consent form Exclusion Criteria: Other diseases than schizophrenia Indulging in an addiction (alcohol, psychoactive substances) over the last 12 months Patient who has received rTMS treatment in the last 12 months Patient who is participating in a concurrent research protocol Patient with a history of seizures rTMS contraindications: patient with epilepsy, brain surgery and/or head trauma in the past, use of cardiac pacemaker, or surgical staples on the scalp MRI contraindications: pregnancy or lactating (n.b. a negative pregnancy test will be required if the patient is a female in reproductive years who does not use contraception); use of cardiac pace maker or surgical staples; patient with a neurological disorder, head trauma or claustrophobia Patient with severe cardiovascular disease Patient with medication which reduces the epileptic threshold (bupropion, methadone and theophylline) Patients placed in psychiatric care either by the state or a third party
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Arezki Ourrad
Phone
+33143093232
Email
urcve1@gmail.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Fanny Thomas, BIOLOGISTE
Organizational Affiliation
Unité de Recherche Clinique, EPS Ville Evrard, Neuilly-sur-Marne,, France, 93330
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Dominique Januel, MD, PhD
Organizational Affiliation
Unité de Recherche Clinique, EPS Ville Evrard, Neuilly-sur-Marne,, France, 93330
Official's Role
Principal Investigator
Facility Information:
Facility Name
Unité de Recherche Clinique, EPS Ville Evrard
City
Neuilly-sur-Marne,
ZIP/Postal Code
93330
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
OURRAD AREZKI, CRA
Phone
0143093030
Email
urcve1@gmail.com

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
31014369
Citation
Thomas F, Bouaziz N, Gallea C, Schenin-King Andrianisaina P, Durand F, Bollore O, Benadhira R, Isaac C, Braha-Zeitoun S, Moulier V, Valero-Cabre A, Januel D. Structural and functional brain biomarkers of clinical response to rTMS of medication-resistant auditory hallucinations in schizophrenia patients: study protocol for a randomized sham-controlled double-blind clinical trial. Trials. 2019 Apr 23;20(1):229. doi: 10.1186/s13063-019-3311-x.
Results Reference
derived

Learn more about this trial

Structural and Functional Correlates of Clinical Response to rTMS Treatment in Schizophrenia Patients With Resistant Auditory Hallucinations

We'll reach out to this number within 24 hrs